Vaxart (VXRT) said late Monday it has completed enrollment of the 400 participants in the sentinel cohort for its phase 2b trial comparing its oral COVID-19 vaccine candidate with an approved mRNA vaccine.
The cohort includes 200 participants receiving Vaxart's vaccine and 200 receiving the mRNA comparator.
The primary endpoint of the study is the relative efficacy of Vaxart's vaccine candidate compared with the mRNA vaccine for the prevention of symptomatic disease, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。